HC Wainwright Comments on Geron’s Q1 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Investment analysts at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Geron in a research report issued to clients and investors on Wednesday, February 26th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.03). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.30 EPS.

Other analysts have also recently issued reports about the stock. Scotiabank lowered their target price on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research note on Thursday, February 27th. Barclays reissued an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC reduced their target price on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and dropped their price target for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Finally, Stifel Nicolaus decreased their target price on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Geron currently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Trading Down 2.8 %

Geron stock opened at $1.71 on Monday. Geron has a one year low of $1.46 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The stock has a market cap of $1.03 billion, a PE ratio of -5.34 and a beta of 0.53. The stock has a 50-day moving average of $2.93 and a two-hundred day moving average of $3.76.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million.

Hedge Funds Weigh In On Geron

Hedge funds and other institutional investors have recently modified their holdings of the business. RTW Investments LP acquired a new stake in shares of Geron in the 3rd quarter worth $200,268,000. Vanguard Group Inc. raised its stake in Geron by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock worth $118,727,000 after purchasing an additional 1,088,912 shares during the period. State Street Corp grew its stake in shares of Geron by 28.4% in the 3rd quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock valued at $131,486,000 after buying an additional 6,413,204 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Geron by 20.0% during the 4th quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock worth $95,769,000 after buying an additional 4,516,615 shares during the last quarter. Finally, Holocene Advisors LP purchased a new stake in shares of Geron during the 3rd quarter valued at approximately $82,498,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.